Suppr超能文献

抗血管内皮生长因子中和抗体对血管生成及微肿瘤生长的完全抑制:活体视频显微镜下血管生成抑制疗法的新概念

Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy.

作者信息

Borgström P, Hillan K J, Sriramarao P, Ferrara N

机构信息

La Jolla Institute for Experimental Medicine, California 92037, USA.

出版信息

Cancer Res. 1996 Sep 1;56(17):4032-9.

PMID:8752175
Abstract

In the present study, we evaluated the effects of a neutralizing antivascular endothelial growth factor (anti-VEGF) antibody on angiogenesis and growth of tumor spheroids using an intravital microscopic technique permitting noninvasive, in vivo and in situ study of tumor angiogenesis and tumor growth in conscious mice. Tumor spheroids of the human rhabdomyosarcoma cell line A673, with a diameter between 600 and 1000 microns, were implanted in dorsal skinfold chambers inserted on Beige nude/xid mice. Tumor cells were prelabeled with a fluorescent vital dye [(5-(and-6)-((4-chloromethyl)benzoyl)amino)tetramethylrhodamine], which allowed estimation of the growth of the implanted tumor spheroids. Treatment (i.p.) with the monoclonal antibody A4.6.1, specific for VEGF, completely inhibited neovascularization of the microtumors and suppressed their growth to the extent that tumors implanted in treated animals leveled off at a volume less than 1 mm3, i.e., the anti-VEGF antibody dramatically changed the growth characteristics of the tumor line from being a rapidly growing malignancy to a dormant microcolony.

摘要

在本研究中,我们使用活体显微镜技术评估了一种中和性抗血管内皮生长因子(抗VEGF)抗体对肿瘤球体血管生成和生长的影响,该技术允许在清醒小鼠体内对肿瘤血管生成和肿瘤生长进行非侵入性、原位研究。将直径在600至1000微米之间的人横纹肌肉瘤细胞系A673的肿瘤球体植入插入米色裸鼠/xid小鼠的背部皮褶小室中。肿瘤细胞用荧光活性染料[(5-(和-6)-((4-氯甲基)苯甲酰基)氨基)四甲基罗丹明]进行预标记,这使得能够估计植入的肿瘤球体的生长情况。用针对VEGF的单克隆抗体A4.6.1进行腹腔注射治疗,完全抑制了微肿瘤的新血管形成,并抑制了它们的生长,以至于植入治疗动物体内的肿瘤在体积小于1立方毫米时趋于稳定,即抗VEGF抗体显著改变了肿瘤细胞系的生长特性,使其从快速生长的恶性肿瘤转变为休眠的微菌落。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验